Adjuvant therapeutic plasma exchange in septic shock

Abstract

Dear Editor, The hallmark of sepsis is a pathological host response to an infection that may lead to organ dysfunction, shock and high mortality. Besides numerous circulating mediators initiating inflammation, vascular barrier breakdown and microvascular hypoperfusion, the consumption and subsequent lack of protective plasmatic factors additionally contribute to sepsis pathophysiology. Immunotherapy is complex and selective inhibition of key molecules, such as TNFα or inflammatory pathways, including Tolllike receptor 4 signaling was so far not effective in men [1]. Therapeutic plasma exchange (TPE) might eliminate circulating injurious mediators in a short intervention and simultaneously replace essential but already consumed protective factors. We have recently demonstrated safety and feasibility of TPE in septic shock in a prospective observational study (POS) [2]. Although uncontrolled by design, efficacy endpoints, such as norepinephrine (NE) requirement, suggested protective effects in these extremely sick patients. Previous studies using TPE in heterogeneous sepsis groups have even implicated potential survival benefits [3–5]. Based on these findings, we hypothesized that a single adjuvant TPE performed within 24 h after onset of septic shock might lead to rapid hemodynamic improvement and therefore performed a pilot bicentric randomized controlled trial (RCT) to test this (Identifier: NCT04231994). We screened patients at two university hospitals for septic shock of < 24 h (+ NE requirement > 0.4 μg/kg/ min despite adequate fluid resuscitation), comparing standard of care (SOC) vs SOC + one single additional TPE (performed immediately following 1:1 envelopebased randomization). TPE was performed against fresh frozen plasma (FFP), exchanging a fixed dose of 12 units of human plasma (3262 ± 350 ml equal to 1 ± 0.3 times plasma volume) within 121 ± 37 min treatment time. Forty patients were randomized based on a power analysis from our earlier POS (n = 20/group, 34 in Hannover, 6 in Bonn). Supplemental Table 1 shows the clinical characteristics highlighting the well-matched cohorts with a comparable severity of disease. The primary endpoint was early hemodynamic improvement (indicated by NE reduction between randomization and 6 h). Despite standard sepsis treatment, the NE dose in the SOC group did not change between randomization and 6 h (NE dose: 0.58 [0.46–0.84] vs 0.48 [0.36–0.84] μg/kg/min, p = 0.15). In contrast, the NE dose fell significantly in the TPE group (0.60 [0.55–0.87] vs 0.34 [0.21–0.44] μg/ kg/min, p < 0.0001, and between-group difference at 6 h: p = 0.004, Fig. 1a). These absolute changes are consistent with a relative NE reduction of − 10% in the SOC group vs − 48% in the TPE group (p = 0.001). The ratio of mean arterial pressure (MAP) to NE dose (MAP/NE) increased within the TPE group (p < 0.0001), while it remained unchanged in the SOC group (p = 0.123) (Fig. 1b), as MAP even increased in the TPE group (p = 0.03) despite profound NE dose reduction, while it was unchanged in the SOC patients (p = 0.52). With regard to key secondary endpoints, the median SOFA score over 9 days (SOC 19 [15–24] vs TPE 16.5 [12–20.5], p = 0.19) and the 28-day survival (SOC 50% vs TPE 60%, p = 0.44) were both not different (Fig. 1c, d). Analysis of predefined secondary *Correspondence: [email protected]; [email protected] 2 Department of Nephrology and Hypertension, Medical School Hannover, Carl-Neuberg-Street 1, 30625 Hannover, Germany Full author information is available at the end of the article